



A DIVERSIFIED TECHNOLOGY COMPANY

Q4 2021 FINANCIAL RESULTS

FEBRUARY 2, 2022

SIMPLE IDEAS. POWERFUL RESULTS.

SAFE HARBOR STATEMENT



The information provided in this presentation contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements may include, among others, statements regarding operating results, the success of our internal operating plans, and the prospects for newly acquired businesses to be integrated and contribute to future growth, profit and cash flow expectations. Forward-looking statements may be indicated by words or phrases such as "anticipate," "estimate," "plans," "expects," "projects," "should," "will," "believes," "intends" and similar words and phrases. These statements reflect management's current beliefs and are not guarantees of future performance. They involve risks and uncertainties that could cause actual results to differ materially from those contained in any forward-looking statement. Such risks and uncertainties include any ongoing impacts of the COVID-19 pandemic on our business, operations, financial results and liquidity, which will depend on numerous evolving factors which we cannot accurately predict or assess, including: the duration and scope of the pandemic, new variants of the virus and the distribution and efficacy of vaccines; any negative impact on global and regional markets, economies and economic activity; actions governments, businesses and individuals take in response to the pandemic; the effects of the pandemic, including all of the foregoing, on our customers, suppliers, and business partners, and how quickly economies and demand for our products and services recover after the pandemic subsides. Such risks and uncertainties also include our ability to identify and complete acquisitions consistent with our business strategies, integrate acquisitions that have been completed, realize expected benefits and synergies from, and manage other risks associated with, the newly acquired businesses, as well as complete the announced divestiture of our TransCore business, including obtaining any required regulatory approvals with respect thereto. We also face other general risks, including our ability to realize cost savings from our operating initiatives, general economic conditions and the conditions of the specific markets in which we operate, changes in foreign exchange rates, difficulties associated with exports, risks associated with our international operations, cybersecurity and data privacy risks, including litigation resulting therefrom, risks related to political instability, armed hostilities, incidents of terrorism, public health crises (such as the COVID-19 pandemic) or natural disasters, increased product liability and insurance costs, increased warranty exposure, future competition, changes in the supply of, or price for, parts and components, including as a result of the current inflationary environment and ongoing supply chain constraints, environmental compliance costs and liabilities, risks and cost associated with litigation, including asbestos related litigation, potential write-offs of our substantial intangible assets, and risks associated with obtaining governmental approvals and maintaining regulatory compliance for new and existing products. Important risks may be discussed in current and subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements. These statements speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events.

We refer to certain non-GAAP financial measures in this presentation. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found within this presentation.

Today's Conference Call Will Discuss Results Primarily on an Adjusted (Non-GAAP) and Continuing Operations Basis.

Q4 Results are Adjusted for the Following Items:

- (1) Acquisition-Related Intangible Amortization Expense
- (2) Purchase Accounting Adjustments to Commission Expense
- (3) Sunquest Trade Name and Technology Asset Impairment Related to Merger with CliniSys
- (4) Income Tax Restructuring Associated with Pending Divestiture

See Appendix for Reconciliations.



- Q4 and 2021 Enterprise Highlights & Financial Results
- 2021 Segment Detail & 2022 Outlook
- 2022 Enterprise Guidance
- Q&A

Strong Close to 2021

- Another Excellent Year For Roper
- Double-Digit Revenue, EBITDA, DEPS, and Cash Flow Growth
- Exceeded 2021 Deleveraging Plans

Considerable Tailwinds Entering 2022


- Software Recurring Revenue Momentum
- Strong Product Demand and Record Backlog
- Reloaded Balance Sheet with Substantial M&A Firepower; Further Amplified by Expected TransCore Proceeds

Well Positioned for Continued Double-Digit Cash Flow Compounding

Q4 FINANCIAL HIGHLIGHTS



- Revenue +13%; Organic Revenue +13%
- EBITDA +12%; EBITDA Margin 38.1%
- DEPS +14% to \$3.73
- Free Cash Flow +4%; 35% of Revenue and 92% of EBITDA



Excellent Q4 Results

Q4 SEGMENT RESULTS



APPLICATION SOFTWARE

Revenue	\$609	+10% vs PY +10% Organic
EBITDA	\$266	43.8% Margin

NETWORK SOFTWARE & SYSTEMS

Revenue	\$355	+15% vs PY +14% Organic
EBITDA	\$186	52.3% Margin

MEASUREMENT & ANALYTICAL SOLUTIONS

Revenue	\$413	+15% vs PY +15% Organic
EBITDA	\$129	31.3% Margin


PROCESS TECHNOLOGIES

Revenue	\$135	+16% vs PY +17% Organic
EBITDA	\$42	31.2% Margin

2021 FINANCIAL HIGHLIGHTS



- Revenue +19%; Organic Revenue +9%
- EBITDA +22%; EBITDA Margin 38.2%
- DEPS +23% to \$14.18
- Free Cash Flow +19%; 31% of Revenue and 82% of EBITDA



Double-Digit Compounding

In \$ millions, except DEPS.


Results are presented on an Adjusted (Non-GAAP) and continuing operations basis. See appendix of this presentation and press release for reconciliations.

* Adjusted for cash taxes paid related to divestitures (2019 & 2020). See appendix for reconciliation.


SUCCESSFUL 2021 DELEVERAGING



NET DEBT*



NET DEBT-TO-EBITDA*



TransCore Proceeds Will Further Amplify M&A Capacity

* Includes discontinued operations.
In \$ millions.


Results are presented on an Adjusted (Non-GAAP) basis. See appendix of this presentation and press release for reconciliations from GAAP to Adjusted results.

SEGMENT DETAIL & OUTLOOK


FY 2021 HIGHLIGHTS

- +8% Organic Revenue Growth Driven by Strong Recurring Revenue (~75% of Segment)
- Deltek Strength Across GovCon and Private Sector; SaaS Tailwind; Favorable End Markets; Gaining Share
- Great Year for Vertafore; Strong Demand from Enterprise Customers; Record Q4 Bookings Add to ARR Momentum
- Combined CliniSys and Sunquest to Create Leading Global Diagnostics and Laboratory Informatics Business Under CliniSys Brand; Horizon Lab Systems Acquisition Broadens Public Health Opportunity
- Aderant Continues to Take Share Led by Strong SaaS Bookings; American LegalNet Acquisition Enhances Docketing Solution
- Strong Subscription Growth for Strata; Successful EPSi Acquisition Further Expands Market Opportunity

REVENUE



EBITDA



Year	Margin
2019	40.0%
2020	42.7%
2021	44.2%


FY 2022 OUTLOOK

- +MSD Organic Growth
 - Driven by Continued Strong Recurring Revenue Growth

FY 2021 HIGHLIGHTS

- +11% Organic Revenue Growth Driven by Strong Recurring Revenue (~80% of Segment)
- Exceptional Year for Freight Matching Businesses; Record Network Expansion Driven by Accelerated Innovation and Favorable Market Conditions
- Recurring Revenue Momentum Across All Network Software Businesses with Strong Execution and Tailwinds:
 - Foundry: Increased Content Creation
 - iTradeNetwork: Food Service Reopening
 - iPipeline: Life Insurance Automation
 - Long-Term Care: Post-COVID Recovery
- Healthcare Solutions Led Growth for rf IDEAS and Inovonics

REVENUE




FY 2022 OUTLOOK

- +HSD Organic Growth
 - Driven by Continued Strong Recurring Revenue Growth

FY 2021 HIGHLIGHTS

- Strong Customer Demand and Backlog as Businesses Broadly Rebounded
- Businesses Executed Well Despite Supply Chain Challenges
- Neptune Record Backlog from Improving Market Conditions and New Product Adoption
- Significant Verathon Growth Versus 2019; Extraordinary Prior Year Comp Drove 2021 Revenue Decline
- NDI and CIVCO Recovered as Healthcare Spending Began to Normalize; Strong Backlog Entering 2022
- Industrial Businesses Rebounded with Better End Market and Capital Spending Environment




FY 2022 OUTLOOK

- +HSD Organic Growth
 - Strong Demand and Backlog
 - Supply Chain Constraints

FY 2021 HIGHLIGHTS

- Strong Demand and Orders with Improving End Market Conditions Across the Segment
- Cornell Growth and Share Gains; Increasing Demand for IoT Pumping Solutions
- Significant Backlog Exiting 2021



FY 2022 OUTLOOK

- Mid-Teens Organic Growth

2022 ENTERPRISE GUIDANCE

- Full Year Adjusted DEPS: \$15.25 - \$15.55
 - Organic Revenue Growth: +6 - 8%
 - Tax Rate: 21 - 22%
- Q1 Adjusted DEPS: \$3.63 - \$3.67

- Another Excellent Year for Roper
 - Revenue +19% to \$5.78B; +9% Organic
 - EBITDA +22% to \$2.21B; EBITDA Margin 38.2%
 - Free Cash Flow +19% to \$1.80B; 31% of Revenue and 82% of EBITDA
 - Exceeded Deleveraging Plan; Reduced Net Debt by \$1.7B
- Entering 2022 With Considerable Tailwinds
 - Strong 2021 Software Recurring Revenue Growth Provides Significant Momentum
 - Record Backlog and Broad-Based Demand Strength for Product Businesses
- \$5B+ of Near-Term M&A Capacity, Including TransCore Proceeds
 - Large Pipeline of High-Quality Acquisition Candidates

Simple Ideas. Powerful Results.

APPENDIX

Q4 INCOME STATEMENT METRICS



	Q4'20	Q4'21	
Revenue	\$1,341	\$1,512	+13%; Organic +13%
Gross Profit	\$906	\$1,018	+12%
Gross Margin	67.6%	67.3%	
EBITDA	\$512	\$576	+12%
EBITDA Margin	38.2%	38.1%	
Interest Expense	\$64	\$56	
Tax Rate	20.1%	21.5%	
Net Earnings	\$347	\$397	+15%
DEPS	\$3.27	\$3.73	+14%

In \$ millions, except DEPS.

Results are presented on an Adjusted (Non-GAAP) and continuing operations basis. See subsequent slides of this presentation and press release for reconciliations.

FULL YEAR INCOME STATEMENT METRICS



	FY'20	FY'21	
Revenue	\$4,866	\$5,779	+19%; Organic +9%
Gross Profit	\$3,283	\$3,918	+19%
Gross Margin	67.5%	67.8%	
EBITDA	\$1,815	\$2,206	+22%
EBITDA Margin	37.3%	38.2%	
Interest Expense	\$211	\$234	
Tax Rate	21.3%	21.2%	
Net Earnings	\$1,221	\$1,510	+24%
DEPS	\$11.55	\$14.18	+23%

In \$ millions, except DEPS.

Results are presented on an Adjusted (Non-GAAP) and continuing operations basis. See subsequent slides of this presentation and press release for reconciliations.

RECONCILIATIONS I



Adjusted Revenue, Gross Profit and EBITDA Reconciliation (\$M)

(From Continuing Operations)

	Q4 2019	Q4 2020	Q4 2021	V %	FY 2019	FY 2020	FY 2021	V %
GAAP Revenue	\$ 1,222	\$ 1,336	\$ 1,512	13%	\$ 4,728	\$ 4,854	\$ 5,778	19%
Purchase accounting adjustment to acquired deferred revenue	5	5	-		11	12	1 ^A	
Adjusted Revenue	<u>\$ 1,227</u>	<u>\$ 1,341</u>	<u>\$ 1,512</u>	<u>13%</u>	<u>\$ 4,738</u>	<u>\$ 4,866</u>	<u>\$ 5,779</u>	<u>19%</u>
GAAP Gross Profit	\$ 812	\$ 901	\$ 1,018		\$ 3,140	\$ 3,271	\$ 3,917	
Purchase accounting adjustment to acquired deferred revenue	5	5	-		11	12	1 ^A	
Adjusted Gross Profit	<u>\$ 817</u>	<u>\$ 906</u>	<u>\$ 1,018</u>	<u>12%</u>	<u>\$ 3,151</u>	<u>\$ 3,283</u>	<u>\$ 3,918</u>	<u>19%</u>
Adjusted Gross Margin	66.6%	67.6%	67.3%	(30 bps)	66.5%	67.5%	67.8%	+30 bps
GAAP Net Earnings	\$ 863	\$ 225	\$ 200		\$ 1,640	\$ 825	\$ 983	
Taxes	237	55	65		417	226	288	
Interest Expense	49	64	56		186	218	234	
Depreciation	12	14	12		43	47	50	
Amortization	103	147	146		366	466	584	
EBITDA	<u>\$ 1,263</u>	<u>\$ 504</u>	<u>\$ 478</u>	<u>(5%)</u>	<u>\$ 2,652</u>	<u>\$ 1,783</u>	<u>\$ 2,139</u>	<u>20%</u>
Purchase accounting adjustment to acquired deferred revenue and commission expense	5	3	(1) ^A		10	10	(5) ^A	
Impairment related to merger of CliniSys and Sunquest	-	-	100 ^B		-	-	100 ^B	
Restructuring charge associated with certain Process Technologies businesses	-	-	-		-	14	-	
Transaction-related expenses for completed acquisitions	-	5	-		6	9	-	
Gain on sale related to minority investment in Sedaru	-	-	-		-	-	(28)	
Gain on sale of Gatan and Scientific Imaging businesses	(801)	-	-		(921)	-	-	
Adjusted EBITDA	<u>\$ 467</u>	<u>\$ 512</u>	<u>\$ 576</u>	<u>12%</u>	<u>\$ 1,748</u>	<u>\$ 1,815</u>	<u>\$ 2,206</u>	<u>22%</u>
% of Adjusted Revenue	38.1%	38.2%	38.1%	(10 bps)	36.9%	37.3%	38.2%	+90 bps

Adjusted Cash Flow Reconciliation (\$M)

(From Continuing Operations)

	Q4 2019	Q4 2020	Q4 2021	V %	FY 2019	FY 2020	FY 2021	V %
Operating Cash Flow	\$ 427	\$ 525	\$ 547	4%	\$ 1,331	\$ 1,368	\$ 1,866	36%
Cash taxes paid on sale of Gatan and Scientific Imaging businesses	-	-	-		39	192	-	
Adjusted Operating Cash Flow	<u>\$ 427</u>	<u>\$ 525</u>	<u>\$ 547</u>	<u>4%</u>	<u>\$ 1,371</u>	<u>\$ 1,560</u>	<u>\$ 1,866</u>	<u>20%</u>
Capital Expenditures	(9)	(7)	(10)		(43)	(28)	(33)	
Capitalized Software Expenditures	(2)	(8)	(7)		(10)	(18)	(30)	
Adjusted Free Cash Flow	<u>\$ 416</u>	<u>\$ 510</u>	<u>\$ 529</u>	<u>4%</u>	<u>\$ 1,318</u>	<u>\$ 1,514</u>	<u>\$ 1,804</u>	<u>19%</u>

Note: Numbers may not foot due to rounding.

RECONCILIATIONS II



Adjusted Revenue Growth Reconciliation

(From Continuing Operations)

Q4 2021	Application Software	Network Software & Systems	Measurement & Analytical Solutions	Process Technologies	Roper
Organic	10%	14%	15%	17%	13%
Acquisitions/Divestitures	-	-	-	-	-
Foreign Exchange	-	-	-	(1%)	-
Rounding	-	1%	-	-	-
Total Adjusted Revenue Growth	10%	15%	15%	16%	13%

Adjusted Segment Reconciliation (\$M)

(From Continuing Operations)

	Application Software		Network Software & Systems		Measurement & Analytical Solutions		Process Technologies	
	Q4 2020	Q4 2021	Q4 2020	Q4 2021	Q4 2020	Q4 2021	Q4 2020	Q4 2021
GAAP Revenue	\$ 549	\$ 609	\$ 310	\$ 355	\$ 360	\$ 413	\$ 117	\$ 135
Purchase accounting adjustment to acquired deferred revenue	5	-	-	-	-	-	-	-
Adjusted Revenue	554	609	310	355	360	413	117	135
GAAP Gross Profit	377	422	253	291	209	230	62	74
Purchase accounting adjustment to acquired deferred revenue	5	-	-	-	-	-	-	-
Adjusted Gross Profit	382	422	253	291	209	230	62	74
Adjusted Gross Margin	69.0%	69.4%	81.6%	82.1%	58.0%	55.8%	53.2%	54.5%
GAAP Operating Profit	132	163	116	143	111	121	35	40
Purchase accounting adjustment to acquired deferred revenue and commission expense	3	(1)	-	-	-	-	-	-
Adjusted Operating Profit	136	162	116	143	111	121	35	40
Adjusted Operating Margin	24.5%	26.6%	37.3%	40.3%	30.8%	29.3%	29.6%	29.8%
Amortization	99	99	41	40	6	5	2	1
Adjusted EBITA	235	261	157	184	116	126	36	42
Depreciation	8	6	2	2	3	3	1	1
Adjusted EBITDA	\$ 242	\$ 266	\$ 159	\$ 186	\$ 119	\$ 129	\$ 37	\$ 42
Adjusted EBITDA Margin	43.7%	43.8%	51.3%	52.3%	33.1%	31.3%	31.7%	31.2%

RECONCILIATIONS III



Adjusted Revenue Growth Reconciliation

(From Continuing Operations)

FY 2021	Application	Network	Measurement	Process	Roper
	Software	Software & Systems	& Analytical Solutions	Technologies	
Organic	8%	11%	8%	8%	9%
Acquisitions/Divestitures	23%	2%	-	-	9%
Foreign Exchange	1%	1%	1%	1%	1%
Rounding	-	-	-	1%	-
Total Adjusted Revenue Growth	32%	14%	9%	10%	19%

Adjusted Segment Reconciliation (\$M)

(From Continuing Operations)

	Application Software			Network Software & Systems			Measurement & Analytical Solutions			Process Technologies		
	FY 2019	FY 2020	FY 2021	FY 2019	FY 2020	FY 2021	FY 2019	FY 2020	FY 2021	FY 2019	FY 2020	FY 2021
GAAP Revenue	\$ 1,588	\$ 1,800	\$ 2,381	\$ 1,004	\$ 1,174	\$ 1,338	\$ 1,544	\$ 1,426	\$ 1,560	\$ 591	\$ 455	\$ 499
Purchase accounting adjustment to acquired deferred revenue	1	8	1	10	4	-	-	-	-	-	-	-
Adjusted Revenue	1,589	1,808	2,382	1,014	1,177	1,338	1,544	1,426	1,560	591	455	499
GAAP Gross Profit	1,065	1,229	1,651	833	954	1,099	904	845	896	338	243	271
Purchase accounting adjustment to acquired deferred revenue	1	8	1	10	4	-	-	-	-	-	-	-
Adjusted Gross Profit	1,065	1,237	1,652	843	957	1,099	904	845	896	338	243	271
Adjusted Gross Margin	67.1%	68.4%	69.3%	83.1%	81.3%	82.1%	58.6%	59.3%	57.4%	57.1%	53.4%	54.4%
GAAP Operating Profit	405	469	636	389	414	512	491	463	483	211	115	153
Purchase accounting adjustment to acquired deferred revenue and commission expense, and restructuring charge associated with certain Process Technologies businesses	-	6	(5)	10	4	-	-	-	-	-	14	-
Adjusted Operating Profit	406	475	631	399	417	512	491	463	483	211	129	153
Adjusted Operating Margin	25.5%	26.3%	26.5%	39.3%	35.5%	38.2%	31.8%	32.5%	30.9%	35.8%	28.4%	30.6%
Amortization	211	275	395	119	162	163	28	22	22	8	6	5
Adjusted EBITA	617	750	1,026	517	580	674	520	486	504	219	135	158
Depreciation	19	22	26	9	9	9	11	12	11	4	3	3
Adjusted EBITDA	\$ 636	\$ 772	\$ 1,052	\$ 526	\$ 589	\$ 683	\$ 531	\$ 497	\$ 516	\$ 223	\$ 139	\$ 161
Adjusted EBITDA Margin	40.0%	42.7%	44.2%	51.9%	50.1%	51.1%	34.4%	34.9%	33.1%	37.6%	30.5%	32.2%

Note: Numbers may not foot due to rounding.

RECONCILIATIONS IV



Adjusted Net Earnings Reconciliation (\$M) ^C

(From Continuing Operations)

	Q4 2020	Q4 2021	V %	FY 2020	FY 2021	V %
GAAP Net Earnings	\$ 225	\$ 200	(11%)	\$ 825	\$ 983	19%
Purchase accounting adjustment to acquired deferred revenue and commission expense	3	(1) ^A		8	(4) ^A	
Impairment related to merger of CliniSys and Sunquest	-	79 ^B		-	79 ^B	
Restructuring charge associated with certain Process Technologies businesses	-	-		11	-	
Transaction-related expenses for completed acquisitions	4	-		13	-	
Amortization of acquisition-related intangible assets ^D	115	113		364	456	
Internal tax restructuring	-	7		-	18	
Gain on sale related to minority investment in Sedaru	-	-		-	(22)	
Adjusted Net Earnings	<u>\$ 347</u>	<u>\$ 397</u>	<u>15%</u>	<u>\$ 1,221</u>	<u>\$ 1,510</u>	<u>24%</u>

Adjusted DEPS Reconciliation ^C

(From Continuing Operations)

	Q4 2020	Q4 2021	V %	FY 2020	FY 2021	V %
GAAP DEPS	\$ 2.12	\$ 1.87	(12%)	\$ 7.81	\$ 9.23	18%
Purchase accounting adjustment to acquired deferred revenue and commission expense	0.03	(0.01) ^A		0.07	(0.04) ^A	
Impairment related to merger of CliniSys and Sunquest	-	0.74 ^B		-	0.74 ^B	
Restructuring charge associated with certain Process Technologies businesses	-	-		0.10	-	
Transaction-related expenses for completed acquisitions	0.03	-		0.12	-	
Amortization of acquisition-related intangible assets ^D	1.09	1.06		3.45	4.28	
Internal tax restructuring	-	0.06		-	0.17	
Gain on sale related to minority investment in Sedaru	-	-		-	(0.20)	
Rounding	-	0.01		-	-	
Adjusted DEPS	<u>\$ 3.27</u>	<u>\$ 3.73</u>	<u>14%</u>	<u>\$ 11.55</u>	<u>\$ 14.18</u>	<u>23%</u>

Forecasted Adjusted DEPS Reconciliation ^C

(From Continuing Operations)

	Q1 2022		FY 2022	
	Low End	High End	Low End	High End
GAAP DEPS	\$ 2.57	\$ 2.61	\$ 11.00	\$ 11.30
Purchase accounting adjustment to acquired deferred revenue and commission expense ^A	(0.01)	(0.01)	(0.03)	(0.03)
Amortization of acquisition-related intangible assets ^D	1.07	1.07	4.28	4.28
Adjusted DEPS	<u>\$ 3.63</u>	<u>\$ 3.67</u>	<u>\$ 15.25</u>	<u>\$ 15.55</u>

RECONCILIATIONS V

(INCLUDING DISCONTINUED OPERATIONS)



Adjusted EBITDA Reconciliation (\$M)

(Including Discontinued Operations)

	<u>FY 2020</u>	<u>FY 2021</u>
GAAP Net Earnings	\$ 950	\$ 1,153
Taxes	260	338
Interest Expense	219	234
Depreciation	53	54
Amortization	467	585
EBITDA	<u>\$ 1,949</u>	<u>\$ 2,364</u>
Purchase accounting adjustment to acquired deferred revenue and commission expense	10	(5) ^A
Impairment related to merger of CliniSys and Sunquest	-	100 ^B
Restructuring charge associated with certain Process Technologies businesses	14	-
Transaction-related expenses for completed acquisitions	9	-
Gain on sale related to minority investment in Sedaru	-	(28)
Adjusted EBITDA	<u>\$ 1,981</u>	<u>\$ 2,432</u>

- A. 2021 actual results and 2022 forecast of estimated acquisition-related fair value adjustments to deferred revenue and commission expense related to the acquisition of Vertafore as shown below (\$M except per share data).

	Q4 2021A	FY 2021A	Q1 2022E	FY 2022E
Pretax	\$ (1)	\$ (5)	\$ (1)	\$ (5)
After-tax	\$ (1)	\$ (4)	\$ (1)	\$ (4)
Per Share	\$ (0.01)	\$ (0.04)	\$ (0.01)	\$ (0.03)

- B. Impairment of \$100M related to merger of CliniSys and Sunquest comprised of trade name (\$95M) and other amortizable intangibles (\$5M).

- C. All 2020, 2021, and 2022 adjustments taxed at 21%.

- D. Actual results and forecast of estimated amortization of acquisition-related intangible assets as shown below (\$M, except per share data).

	Q4 2020A	FY 2020A	Q4 2021A	FY 2021A	Q1 2022E	FY 2022E
Pretax	\$ 146	\$ 461	\$ 143	\$ 577	\$ 145	\$ 581
After-tax	\$ 115	\$ 364	\$ 113	\$ 456	\$ 115	\$ 459
Per share	\$ 1.09	\$ 3.45	\$ 1.06	\$ 4.28	\$ 1.07	\$ 4.28

Discontinued Operations:

During 2021, Roper signed definitive agreements to divest its TransCore, Zetec, and CIVCO Radiotherapy businesses. Roper has completed the divestitures of Zetec and CIVCO Radiotherapy and expects the TransCore transaction to close in the first quarter of 2022, subject to customary closing conditions, including regulatory approvals. The financial results for these businesses are reported as discontinued operations for all periods presented.



A DIVERSIFIED TECHNOLOGY COMPANY